Animal models related to congenital heart disease and clinical research in pulmonary hypertension

Cardiology

Volumn 116, Issue 1, 2010, Pages 18-25

  Loukanov, Tsvetomir ^a   Geiger, Ralf ^c   Agrawal, Rahul ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Animal models; Cinaciguat; Congenital heart disease; CTEPH; Elastase inhibition; Iloprost; Pulmonary arterial hypertension; Pulmonary hypertension; Riociguat; Soluble guanylate cyclase; Tyrosin kinase inhibition

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; BAY 63 2521; BOSENTAN; CINACIGUAT; ELASTASE; ELASTASE INHIBITOR; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; ILOPROST; IMATINIB; NITRIC OXIDE; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RIOCIGUAT; RIVAROXABAN; SORAFENIB; TEZOSENTAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL MODEL; BLALOCK TAUSSIG SHUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EXERCISE; HEART LEFT RIGHT SHUNT; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SINGLE DRUG DOSE; STROKE; SWINE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; PYRAZOLES; PYRIMIDINES; VASODILATOR AGENTS;

EID: 77951251619     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313865     Document Type: Review

References (30)

1. Heath D: The rat is a poor animal model for the study of human pulmonary hypertension. Cardioscience 1992; 3: 1-6.
2. Reddy VM, Meyrick B, Wong J, et al: In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation 1995; 92: 606-613.
3. Geiger R, Pajk W, Neu N, et al: Tezosentan decreases pulmonary artery pressure and improves survival rate in an animal model of meconium aspiration. Pediatr Res 2006; 59: 147-150.
4. Soukka H, Rautanen M, Halkola L, et al: Meconium aspiration induces ARDS-like pulmonary response in lungs of ten-week-old pigs. Pediatr Pulmonol 1997; 23: 205-211.
5. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349.
6. Haddad F, Doyle R, Murphy DJ, et al: Right ventricular function in cardiovascular disease. II. Pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008; 117: 1717-1731.
7. Haddad F, Hunt SA, Rosenthal DN, et al: Right ventricular function in cardiovascular disease. I. Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008; 117: 1436-1448.
8. Vieillard-Baron A, Jardin F: Why protect the right ventricle in patients with acute respiratory distress syndrome? Curr Opin Crit Care 2003; 9: 15-21. Review. (Pubitemid 36157374)
9. Geiger R, Kleinsasser A, Meier S, et al: Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration. Intensive Care Med 2008; 34: 368-376.
10. Malhotra A: Low-tidal-volume ventilation in the acute respiratory distress syndrome. N Engl J Med 2007; 357: 1113-1120.
11. Pircher I, Schwienbacher M, Geiger R, et al: Intensive Care Medicine. Submitted.
12. Lopez AD, Murray CCJL: The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
13. Galiè N, Hoeper MM, Humbert M, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
14. Rosenkranz S, et al: Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007; 96: 527-541.
15. Simonneau G, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(1 suppl S):S43-S54.
16. McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
17. Olschewski H, Simmoneau G, Galiè N, et al: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
18. Lee SD, Shroyer KR, Markham NE, et al: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-934.
19. Klein M, Schermuly RT, Ellinghaus P, et al: Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008; 118: 2081-2090.
20. Schmidt HH, Schmidt PM, Stasch JP: NOand haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 2009;191: 309-339.
21. Ghofrani HA, Grimminger F: Modulating cGMP to treat lung diseases. Handb Exp Pharmacol 2009;191: 469-483.
22. Boerrigter G, Lapp H, Burnett JC: Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol 2009;191: 485-506.
23. Stasch JP, Becker EM, Alonso-Alija C, et al: NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-215. (Pubitemid 32216593)
24. Evgenov OV, Ichinose F, Evgenov NV, et al: Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004; 110: 2253-2259.
25. Dumitrascu R, Weissmann N, Ghofrani HA, et al: Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-295.
26. Evgenov OV, Pacher P, Schmidt PM, et al: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5: 755-768.
27. Schermuly RT, Stasch JP, Pullamsetti SS, et al: Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891.
28. Frey R, Mück W, Unger S, et al: Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending- dose study in healthy male volunteers. J Clin Pharmacol 2008; 48: 926-934.
29. Grimminger F, Weimann G, Frey R, et al: First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
30. Ghofrani HA, Hoeper MM, et al: Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2009; 179:A3337.